Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Source：MarketWatch
友情提醒：請廣大讀者理性看待市場資訊，切實提高風險意識。站內所有內容僅系市場資訊或相關方觀點，不構成任何形式投資建議。